Pacific Biosciences (PACB) 8.60 $PACB Coverage of

New Post Public Reply Private Reply Replies (0) Message Board

Jun 23, 2016 at 9:08 PM

Pacific Biosciences (PACB) 8.60 $PACB

Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 15.01 (+0.18), PACB: 8.60 (-0.19), AVXL: 4.27 (+0.12), PPHM: 0.40 (+0.01)

What Caused Illumina's Shares to Crash 19% In April
Todd Campbell, The Motley Fool - Motley Fool - Thu May 05, 7:20AM CDT
SOURCE: ILLUMINA INC. What: After pre-announcing a revenue and profit shortfall, Illumina saw its shares lose 19.1% of their value last month, according to data from S&P Global Market Intelligence . So what: The maker of instruments...
PACB: 8.60 (-0.19), TMO: 152.14 (+2.29), ILMN: 146.59 (+5.70)

Pacific Biosciences and Advanced Analytical Technologies Announce Co-Marketing Agreement
GlobeNewswire - Tue Apr 26, 6:30AM CDT
Pacific Biosciences of California, Inc., (Nasdaq

ACB) and Advanced Analytical Technologies, Inc., (AATI) today announced the companies have signed an agreement to jointly promote their technology solutions for long-read DNA sequencing.
PACB: 8.60 (-0.19)

Is Pacific Biosciences or Illumina Corp. a Better Buy?
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 25, 7:20AM CDT
SOURCE: ILLUMINA CORP. After reporting preliminary sales figures that were south of industry watchers' forecasts, shares in gene-sequencing giant Illumina Corp. toppled this week. Meanwhile, better-than-anticipated sales at Illumina's smaller...
PACB: 8.60 (-0.19), ILMN: 146.59 (+5.70)

Why Shares of Pacific Biosciences of California Spiked 19% Today
Travis Hoium, The Motley Fool - Motley Fool - Fri Apr 22, 2:58PM CDT
The Sequel System. Image source: Pacific Biosciences. What: Shares of DNA sequencing company Pacific Biosciences of California jumped as much as 19% today after the company reported first-quarter earnings. So what: Revenue rose 8% from a...
PACB: 8.60 (-0.19)

Pacific Biosciences of California Pushing Toward Sustainable Growth
Travis Hoium, The Motley Fool - Motley Fool - Fri Apr 22, 8:20AM CDT
First-quarter 2016 earnings from gene sequencer Pacific Biosciences of California were released after the market closed on Thursday, and the company's transition to sustainable long-term viability continued. The company launched the Sequel System...
PACB: 8.60 (-0.19)

Pacific Biosciences (PACB) Q1 Loss Narrower than Expected
Zacks Equity Research - Zacks Investment Research - Fri Apr 22, 7:21AM CDT
Pacific Biosciences of California Inc. (PACB) reported a decent first-quarter 2016, thanks to the growing demand for its new Sequel system.
PACB: 8.60 (-0.19), GMED: 23.91 (+0.67), INGN: 47.45 (+2.56), EXAC: 26.30 (+0.18)

Pacific Biosciences reports 1Q loss
Automated Insights - Thu Apr 21, 4:02PM CDT
MENLO PARK, Calif. (AP) _ Pacific Biosciences of California Inc. (PACB) on Thursday reported a loss of $19.4 million in its first quarter.
PACB: 8.60 (-0.19)

Pacific Biosciences of California, Inc. Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu Apr 21, 3:00PM CDT
Pacific Biosciences of California, Inc. (NASDAQ

ACB) today announced financial results for its first quarter ended March 31, 2016.
PACB: 8.60 (-0.19)

Illumina's Gene Sequencers Are About to Revolutionize Healthcare
Motley Fool Staff - Motley Fool - Wed Apr 20, 7:21AM CDT
Over 7,500 of Illumina Corp 's gene sequencing machines are already being used by researchers globally to advance our understanding of DNA and DNA's relationship with disease. Discoveries stemming from this research are leading...
PACB: 8.60 (-0.19), TMO: 152.14 (+2.29), ILMN: 146.59 (+5.70)

Are Illumina's Shares Worth Buying on This Drop?
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 5:21PM CDT
Image source: Illumina Inc. After the closing bell yesterday, Illumina 's management surprised investors with lackluster preliminary first-quarter sales that caused shares in the gene sequencing giant to plummet. With shares deeply discounted...
PACB: 8.60 (-0.19), TMO: 152.14 (+2.29), ILMN: 146.59 (+5.70)

Why Illumina Shares Are Tanking 18% Pre-Market
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 7:36AM CDT
SOURCE: ILLUMINA CORP What: After issuing preliminary revenue for the first quarter that was below industry watcher's targets, shares of Illumina are indicated to open lower by 18% today as of 8:30 a.m. EST. So what: The maker of machines...
PACB: 8.60 (-0.19), ILMN: 146.59 (+5.70)

What Awaits Pacific Biosciences (PACB) in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Apr 19, 7:12AM CDT
Pacific Biosciences of California Inc. (PACB) is scheduled to report first-quarter 2016 results on Apr 21.
BDX: 172.19 (+2.22), PRXL: 60.51 (+1.06), PACB: 8.60 (-0.19), ALGN: 81.82 (+1.40)

Healthcare's Future: Science Fiction or Science Fact
Todd Campbell and Kristine Harjes, The Motley Fool - Motley Fool - Sat Apr 16, 11:03AM CDT
The potential to revolutionize healthcare is being driven by significant advances in technology that may improve patient procedures and usher in an era of personalized medicine. At the forefront of this innovation are Intuitive Surgica l's robotic...
ISRG: 661.32 (+9.87), PACB: 8.60 (-0.19), ILMN: 146.59 (+5.70), TRXC: 1.39 (+0.07)

Pacific Biosciences of California, Inc. First Quarter 2016 Financial Results Call
GlobeNewswire - Tue Apr 05, 4:18PM CDT
Pacific Biosciences of California, Inc. (NASDAQ

ACB) will hold its quarterly conference call to discuss its First Quarter 2016 Financial Results on Thursday, April 21, 2016, at 4:30pm Eastern Time.
PACB: 8.60 (-0.19)

14.1% Return Seen to Date on SmarTrend Pacific Biosciences of California Call (PACB)
Comtex SmarTrend(R) - Fri Apr 01, 1:43PM CDT
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQ

ACB) on January 28th, 2016 at $10.73. In approximately 2 months, Pacific Biosciences of California has returned 14.13% as of today's recent price of $9.21.
PACB: 8.60 (-0.19)

PacBio's SMRT Sequencing Provides Scientists with a Superior Gorilla Genome Reference
GlobeNewswire - Thu Mar 31, 1:00PM CDT
Pacific Biosciences of California, Inc., (Nasdaq

ACB) the pioneer and leader in long-read sequencing using its Single Molecule, Real-Time (SMRT) technology, today announced that scientists from the University of Washington, the McDonnell Genome Institute at Washington University in St. Louis, and other institutions have published the best genome assembly of the gorilla to date -- more than 150-fold improvement over previous assemblies -- using long-read SMRT Sequencing from Pacific Biosciences. The peer-reviewed paper appears in the April 1 issue of the journal Science and is available online today.
PACB: 8.60 (-0.19)

Pacific Biosciences of California Shares Down 27.8% Since SmarTrend's Sell Call (PACB)
Comtex SmarTrend(R) - Thu Mar 24, 12:40AM CDT
SmarTrend identified a Downtrend for Pacific Biosciences of California (NASDAQ

ACB) on January 28th, 2016 at $10.73. In approximately 2 months, Pacific Biosciences of California has returned 27.83% as of today's recent price of $7.74.
PACB: 8.60 (-0.19)

Look for Shares of Pacific Biosciences of California to Potentially Pullback after Yesterday's 1.44% Rise
Comtex SmarTrend(R) - Mon Mar 21, 4:54PM CDT
Pacific Biosciences of California (NASDAQ

ACB) traded in a range yesterday that spanned from a low of $8.27 to a high of $8.73. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $8.66 on volume of 505,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PACB: 8.60 (-0.19)

Is This the Biggest Threat Yet to Illumina?
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 18, 4:41PM CDT
IMAGE SOURCE: ILLUMINA INC. Illumina has held go-to status as the dominant maker of gene-sequencing devices for years, but a new, next-generation gene-sequencing machine made by Pacific Biosciences aims to change that. Can Illumina fend off...
PACB: 8.60 (-0.19), ILMN: 146.59 (+5.70)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

oToBrite Unveils Avant-Garde Robotics Vision Tech at ROBOTWORLD

An Eye on the Future: oToBrite's Bold Vision for Robotics Strolling down the aisles at ROBOTWORLD 2026, there's a palpable energy buzzing around oToBrite's booth. These folks are showcasing vision technology that's not just about snapping slick photos—it's about reshaping how machines see the world. And, let me tell you, if there’s one place to flaunt cutting-edge...

QFIN Faces Lawsuit Over Broken Promises and Revenue Plunge

Unmasking the Hype: QFIN's Pledge and Performance Investors, gather 'round because QFIN's latest uproar ain't pretty. The folks over at Qfin Holdings have found themselves in hot water, facing a class action lawsuit for allegedly pulling the wool over investors' eyes. Between March and August 2026, they promised a rock-solid ship braving China’s regulatory storm. Turns...

Innovative Trial Targets Drug Resistance in Lung Cancer

The Battle Against Drug Resistance Heats Up Folks, we're in a never-ending fight here against one of the toughest adversaries out there: lung cancer. And lemme tell ya, when drugs show resistance, it's like trying to punch a ghost. But there’s a fresh wind blowing, as Dr. Bobak Parang steps up to the plate with a $620K grant aimed squarely at tackling drug resistance in...

Unlocking Geothermal's Heat Potential in Europe

An Overlooked Powerhouse: Geothermal Heat in Industry These days, it feels like everyone’s got their head in the clouds about renewables—think wind and solar. But under the surface, literally, is geothermal energy, waiting to make a play in Europe’s industrial sector. Project InnerSpace and Future Cleantech Architects are spotlighting a sleeping giant with their...

West Fraser Tackles Grim Quarter: Indefinite Mill Closures

Bracing For Impact: The Tough Truth About West Fraser's Recent Moves Things are looking a bit bleak over at West Fraser Timber Co. They've just dropped their Q3 2026 results, ringing the bell with a hefty $80 million loss. As if that wasn't enough, the company's decided to indefinitely curtail a couple of mills—one in Lanett, Alabama and the other in Leola, Arkansas....

LUNGevity's Bold $1M Bet on Lung Cancer Research

Investing in the Future of Lung Cancer Research Damn, you don't see this kind of commitment every day! LUNGevity Foundation is dropping over a million bucks on the table to swell the ranks of lung cancer researchers. They're not just tossing dollars at established players; they're betting on fresh minds to shake things up in this critical field. Tackling lung cancer isn't...

SHEIN Expands Compliance Training With UL Solutions

Boosting Seller Compliance Amid Global Standards When you're navigating the cutthroat world of online retail, product compliance isn't just a checkbox—it's your lifeline. SHEIN, a name you're likely familiar with if you're into fast fashion, is doubling down on this by teaming up with UL Solutions. They're holding hands and marching into another training session focused...

Rothera's KPI Swap Approval: A Financial Game Changer

Revolutionizing Risk Management with KPI Swaps Boy, if there's one thing that gets my ticker going, it's the buzz of innovation in financial markets. Rothera just landed a CFTC stamp of approval for something that's about to shake up how institutional traders manage risk: Key Performance Indicator (KPI) swaps. And can you believe it? This isn't just another derivative...

Regal Healthcare: Five Years of Founder-Friendly Valor

Why Founder-Friendly Matters More Than Ever in Healthcare Well folks, in a year when everyone's tossing around terms like 'value-added' and 'strategic support', seeing Regal Healthcare Capital Partners snag slot number five straight on Inc.'s Founder-Friendly Investors list feels like catching a rare breed of fish twice. Seriously, these folks are stamping their forte as...

Jacobi's Harness Brings AI from Concept to Reality

The Challenge of Moving AI to Production Diving headfirst into AI in finance? Well, Jacobi's bold move with their new toy, the Investment Management Harness, spotlights a filthy secret: the hurdles between a big idea and execution are seldom technological. We got AI shaving prototyping time down to just days, yet pushing to production? That's a marathon in itself. Boards...